Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 80

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 80
---
 OTC Markets under the symbols “DNQUF,” “DNQAF” and
“DNQWF,” respectively.

On January 25, 2023, Denali entered into an Agreement and Plan of Merger (the “Longevity Merger
Agreement”), by and among Longevity Biomedical, Inc., a Delaware corporation (“Longevity”), Denali SPAC

34

Holdco, Inc., a Delaware corporation and direct, wholly owned subsidiary of Denali (“Holdco”), Denali SPAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary
of Holdco (“Denali-Longevity Merger Sub”), Longevity Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of Holdco (“Longevity Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller
representative (the “Seller Representative”).

Pursuant to the Longevity Merger Agreement, the parties thereto were to enter into a business
combination transaction (the “Longevity Business Combination” and, together with the other transactions contemplated by the Longevity Merger Agreement, the “Longevity Transactions”), pursuant to which, among other things,
immediately following the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC, (i) the Denali-Longevity Merger Sub would merge with and into Denali (the
“Denali-Longevity Merger”), with Denali as the surviving entity of the Denali-Longevity Merger, and (ii) Longevity Merger Sub would merge with and into Longevity (the “Longevity Merger”), with Longevity as the surviving
company of the Longevity Merger. Afterwards, each of Longevity and Denali would be a subsidiary of Holdco, and Holdco would become a publicly traded company.

On October 11, 2023, Denali held an extraordinary general meeting of shareholders (the “Extension Meeting”). At the Extension Meeting, the
Denali shareholders approved amendments to the Current Denali Charter to, among other things, extend the date by which Denali must (i) consummate an initial business combination; (ii) cease its operations, except for the purpose of winding
up, if it fails to complete such initial business combination; and (iii) redeem 100% of Denali Class A Ordinary Shares, from October 11,